← Zealand Pharma A/S/ADR (ZLDPF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zealand Pharma A/S/ADR (ZLDPF)
Biotechnology · market cap $2.9B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Zealand Pharma A/S (ZLDPF) is a Danish biotechnology company with a market cap of approximately $3.26B and a share price near $48.12. Its pipeline is anchored by dasiglucagon in Phase 3 for Congenital Hyperinsulinism (CHI), alongside glepaglutide (Phase 3, Short Bowel Syndrome), petrelintide (Phase 2, overweight/obesity), and GlucaGen (Phase 3, hypoglycemia). The provided fact set contains significant data gaps — no financials, cash runway, analyst coverage, or near-term catalyst dates are available — limiting the precision of any assessment.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| dasiglucagon | Phase 3 | Congenital Hyperinsulinism |
| Glepaglutide | Phase 3 | Short Bowel Syndrome |
| Petrelintide | Phase 2 | Overweight |
| GlucaGen | Phase 3 | Hypoglycemia |
| Thiotepa | Phase 3 | Acute Lymphoblastic Leukaemia |
Price & technical context
3-month
-18.8%
6-month
-14.8%
12-month
-46.3%
52-wk range
$38.10–$83.12
vs 50-day MA
-18.5%
vs 200-day MA
-26.3%
Realized vol
66.8%
Max drawdown
-72.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZLDPF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.